


## SUPPLEMENTAL FIGURE 1

## Fate of HPV infections present at the time of vaccination: cohort of women without high-grade disease




HPV, human papillomavirus.

Hildesheim et al. HPV vaccination after infection and/or treatment. *Am J Obstet Gynecol* 2016.

## SUPPLEMENTAL FIGURE 2

## Fate of HPV infections present at the time of vaccination-cohort of women without low grade or high grade disease



Hildesheim et al. HPV vaccination after infection and/or treatment. *Am J Obstet Gynecol* 2016.

SUPPLEMENTAL TABLE 1

## Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP (prevalent infections)

HPV types	Arm	No. trials	No. events (infections)	No. person-years	Rate per 1000	%VE	95% CI
HPV-16/18	HPV	66	8	153	52.5		
	Ctrl	115	8	223	36.0	-46.0%	[-302, 47]
HPV-31/33/45	HPV	52	4	126	31.8		
	Ctrl	81	3	142	21.2	-50.1%	[-595, 68]
HPV-Onco	HPV	263	25	592	40.0		
	Ctrl	422	20	787	24.2	-65.4%	[-204, 10]
			No. events (persistent infections)				
HPV-16/18	HPV	66	4	156	25.7		
	Ctrl	114	4	225	17.9	-44.2%	[-498, 65]
HPV-31/33/45	HPV	52	2	128	15.6		
	Ctrl	80	1	142	7.0	-121.6%	[-2409, 80]
HPV-Onco	HPV	263	14	612	21.3		
	Ctrl	419	9	790	10.6	-100.5%	[-389, 18]
			No. events (LSIL+)				
HPV-16/18	HPV	142	4	302	13.2		
	Ctrl	169	2	326	6.1	-116.0%	[-1092, 61]
HPV-31/33/45	HPV	142	3	302	9.9		
	Ctrl	169	1	326	3.1	-224.0%	[-3048, 67]
HPV-Onco	HPV	142	10	302	33.1		
	Ctrl	169	3	326	9.2	-260.0%	[-1230, 2.5]
			No. events (HSIL+)				
HPV-16/18	HPV	142	3	348	8.6		
	Ctrl	169	1	367	2.7	-216.0%	[-2961, 67]
HPV-31/33/45	HPV	142	3	348	8.6		
	Ctrl	169	0	367	0.0	N/A	N/A
HPV-Onco	HPV	142	6	348	17.2		
	Ctrl	169	1	367	2.7	-532.0%	[-5183, 24]
			No. events (CIN2+)				
HPV-16/18	HPV	142	3	362	8.3		
	Ctrl	169	1	375	2.7	-211.1%	[-2901, 68]
HPV-31/33/45	HPV	142	0	362	0.0		
	Ctrl	169	0	375	0.0	N/A	N/A
HPV-Onco	HPV	142	3	362	8.3		
	Ctrl	169	1	375	2.7	-211.1%	[-2901, 68]

CI, confidence interval; CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; Ctrl, control; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excisional procedure; LSIL, low-grade squamous intraepithelial lesion; N/A, not available; VE, vaccine efficiency.

Hildesheim et al. HPV vaccination after infection and/or treatment. Am J Obstet Gynecol 2016.

SUPPLEMENTAL TABLE 2

## Impact of HPV-16/18 vaccination on recurrence of HPV infections and cervical lesions after LEEP (new infections)

HPV types	Arm	No. trials	No. events (infections)	No. person-years	Rate per 1000	%VE	95% CI
HPV-16/18	HPV	206	4	526	7.6		
	Ctrl	209	8	441	18.0	57.9%	[−43, 88]
HPV-31/33/45	HPV	356	5	912	5.7		
	Ctrl	405	17	847	21.0	72.9%	[29, 90]
HPV-Onco	HPV	1369	46	3504	11.2		
	Ctrl	1522	65	3182	17.7	36.7%	[1.5, 59]
			No. events (persistent infections)				
HPV-16/18	HPV	206	0	533	0.0		
	Ctrl	208	2	441	4.5	100.0%	N/A
HPV-31/33/45	HPV	356	0	920	0.0		
	Ctrl	404	7	858	8.6	100.0%	N/A
HPV-Onco	HPV	1369	8	3544	2.2		
	Ctrl	1517	21	3211	6.5	65.5%	[23, 84]
			No. events (LSIL+)				
HPV-16/18	HPV	142	0	302	0.0		
	Ctrl	169	2	326	6.1	100.0%	N/A
HPV-31/33/45	HPV	142	2	302	6.6		
	Ctrl	169	4	326	12.3	46.0%	[−194, 90]
HPV-Onco	HPV	142	9	302	29.8		
	Ctrl	169	10	326	30.6	2.8%	[−140, 61]
			No. events (HSIL+)				
HPV-16/18	HPV	142	0	348	0.0		
	Ctrl	169	1	367	2.7	100.0%	N/A
HPV-31/33/45	HPV	142	0	348	0.0		
	Ctrl	169	0	367	0.0	N/A	N/A
HPV-Onco	HPV	142	1	348	2.9		
	Ctrl	169	2	367	5.4	47.3%	[−480, 95]
			No. events (CIN2+)				
HPV-16/18	HPV	142	0	362	0.0		
	Ctrl	169	0	375	0.0	N/A	N/A
HPV-31/33/45	HPV	142	0	362	0.0		
	Ctrl	169	0	375	0.0	N/A	N/A
HPV-Onco	HPV	142	0	362	0.0		
	Ctrl	169	1	375	2.7	100.0%	N/A

CI, confidence interval; CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; Ctrl, control; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LEEP, loop electrosurgical excisional procedure; LSIL, low-grade squamous intraepithelial lesion; N/A, not available; VE, vaccine efficiency.

Hildesheim et al. HPV vaccination after infection and/or treatment. Am J Obstet Gynecol 2016.

1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734

**000** Impact of human papillomavirus (HPV) 16 and 18 vaccination  
on prevalent infections and rates of cervical lesions after  
excisional treatment

Allan Hildesheim; Paula Gonzalez; Aimee R. Kreimer; Sholom Wacholder;  
John Schussler; Ana C. Rodriguez; Carolina Porras; Mark Schiffman;  
Mary Sidawy; John T. Schiller; Douglas R. Lowy; Rolando Herrero; for the Costa  
Rica HPV Vaccine Trial (CVT) Group

1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790